Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Locus Cell CoROCO:6891 -2.89%22 Piotroski F-Score is 2 as of Aug. 13, 2026, which is 50% below its 10-year median of 4.00. GuruFocus rates ROCO:6891 with a GF Score™ of 22/100 and a GF Value™ of NT$778.63 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,320 Biotechnology companies, Locus Cell Co ranks worse than 72.95% on this metric.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Locus Cell Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Locus Cell Co's Piotroski F-Score or its related term are showing as below:
ROCO:6891'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 4 Max: 5
Current: 2
During the past 6 years, the highest Piotroski F-Score of Locus Cell Co was 5. The lowest was 2. And the median was 4.
Locus Cell Co (ROCO:6891) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Locus Cell Co Piotroski F-Score Related Terms
Locus Cell Co Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Locus Cell Co's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6891 vs VRTX, REGN, RVMD: Piotroski F-Score Comparison
For the Biotechnology subindustry, Locus Cell Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Locus Cell Co Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Locus Cell Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Locus Cell Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Locus Cell Co's current Net Income (TTM) was -181.54.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Locus Cell Co's return on assets of this year was -0.09980297. Locus Cell Co's return on assets of last year was -0.05900633.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Locus Cell Co's gearing of this year was 0.15273945. Locus Cell Co's gearing of last year was 0.03111607.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Locus Cell Co's current ratio of this year was 13.57964163. Locus Cell Co's current ratio of last year was 31.00921695.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Locus Cell Co's number of shares in issue this year was 200.01. Locus Cell Co's number of shares in issue last year was 200.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Locus Cell Co's gross margin of this year was 0.492542. Locus Cell Co's gross margin of last year was 0.70882852.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Locus Cell Co's asset turnover of this year was 0.00700273. Locus Cell Co's asset turnover of last year was 0.00123007.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
0
+
0
+
0
+
0
+
1
=
2
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Locus Cell Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
Locus Cell Co (ROCO:6891) has a Piotroski F-Score of 2 as of Aug. 13, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Locus Cell Co and its competitors. This is 50% below median its historical median of 4.00. Over the past decade, Locus Cell Co's Piotroski F-Score has ranged from 2.00 to 5.00. According to the industry distribution chart, Locus Cell Co ranks #963 out of 1320 companies in the Biotechnology industry, placing it in the top 73%.
Is Locus Cell Co's Piotroski F-Score too high?
Locus Cell Co's current Piotroski F-Score of 2 is 50% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. Locus Cell Co's value of 2 is 33.3% below this industry median. Based on the distribution chart, Locus Cell Co ranks #963 out of 1320 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Locus Cell Co has a GF Score™ of 22/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Locus Cell Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Locus Cell Co ranks #963 out of 1320 companies for Piotroski F-Score. This places Locus Cell Co in the lower half of its industry. The industry median Piotroski F-Score is 3.00. Locus Cell Co's value of 2 is 33.3% below this benchmark. Historically, Locus Cell Co's own Piotroski F-Score has ranged from 2.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Locus Cell Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,320 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Locus Cell Co's current Piotroski F-Score of 2 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Locus Cell Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Locus Cell Co's current Piotroski F-Score is 2, which is 50% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Locus Cell Co stock overvalued right now?
Based on GuruFocus' analysis, Locus Cell Co (ROCO:6891) is currently considered Possible Value Trap. The stock's GF Value™ is NT$778.63, compared to a current price of NT$38.65 — trading 95% below its estimated fair value. The current Piotroski F-Score is 2, which is 50% below median its 10-year median of 4.00 and 33.3% below the Biotechnology industry median of 3.00. Locus Cell Co's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Locus Cell Co (ROCO:6891), the current Piotroski F-Score is 2 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Locus Cell Co (ROCO:6891) Overvalued in 2026?
Based on GuruFocus' analysis, Locus Cell Co stock appears to be undervalued.
The current stock price of NT$38.65 is trading 95% below its estimated GF Value™ of NT$778.63.
GuruFocus considers Locus Cell Co to be Possible Value Trap.
Key valuation signals for ROCO:6891:
Piotroski F-Score: 2 (50% below median its 10-year median of 4.00)
GF Value™: NT$778.63 vs. price of NT$38.65 (95% below fair value)
Industry Position: 33.3% below the Biotechnology median (#963 of 1320)
No single metric tells the full story. See the ROCO:6891 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6891 has been successfully added to your 
